US ATTR Amyloidosis Pricing Strategy Model

Tafamidis (Vyndaqel/Vyndamax, Pfizer) carries a US price near $268,000 a year on a WAC basis close to $225,000, and ICER's October 2024 review judged the entire TTR-stabilizer class priced roughly 85 to 95 percent above a cost-effective level: a fair-value benchmark of $13,000 to $17,000 a year. That gap, 12 to 17 times list, is the largest value mismatch in the rare-disease pricing basket AXLRx tracks. Despite Medicare spend among the highest of any orphan category, tafamidis sits outside CMS's Inflation Reduction Act drug-price negotiation. It is absent from the first three negotiation cycles, IPAY 2026 through 2028, shielded by the orphan-drug exclusion that the 2025 tax-and-spending law broadened to cover drugs carrying multiple orphan designations, a protection that extends across the whole ATTR stabilizer and silencer set.

With Medicare negotiation off the table, net price is set by competition, not by a payer at the negotiating table. Acoramidis (Attruby, BridgeBio) launched in November 2024 below tafamidis's list price, giving payers two-stabilizer leverage to negotiate deeper rebates on a shared Part D tier, and a pending generic tafamidis adds further compression on top. Commercial and Medicare Part D plans already negotiate net prices 40 to 60 percent below WAC through rebates, well before any generic enters. Benefit routing splits the market further: oral stabilizers route through Part D, where the IRA's $2,000 annual out-of-pocket cap now shields patients, while the infused or injected RNA silencers route through the Part B medical benefit at ASP-plus-6%. A new entrant's pricing model has to hold WAC positioning, ICER exposure, rebate depth, and Part D versus Part B routing in the same view.

Every AXLRx pricing model is built from primary regulatory and HTA sources, CMS selected-drug fact sheets, ICER final evidence reports, and FDA approval records, not secondary summaries. Findings are independently verified before inclusion.

US ATTR pricing sources: the ICER October 2024 ATTR-CM Final Evidence Report, the CMS Medicare Drug Price Negotiation selected-drug fact sheets confirming tafamidis's absence from IPAY 2026-2028, FDA Drugs@FDA for approval dates, and BridgeBio's public acoramidis launch pricing disclosures.